A retrospective study analysing overall survival and time to progression in RAS-wild type metastatic colorectal cancer treated with cetuximab or panitumumab as third or subsequent line therapy
Latest Information Update: 28 Jul 2020
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Panitumumab (Primary)
- Indications Cancer metastases; Colorectal cancer
- Focus Therapeutic Use
- 28 Jul 2020 New trial record
- 04 Jul 2020 Results presented at the 22nd World Congress on Gastrointestinal Cancer